Cancer Cell 2017-07-10

Oncogenic Activation of the RNA Binding Protein NELFE and MYC Signaling in Hepatocellular Carcinoma

Hien Dang, Atsushi Takai, Marshonna Forgues, Yotsowat Pomyen, Haiwei Mou, Wen Xue, Debashish Ray, Kevin C.H. Ha, Quaid D. Morris, Timothy R. Hughes, Xin Wei Wang

Index: 10.1016/j.ccell.2017.06.002

Full Text: HTML

Abstract

Global transcriptomic imbalance is a ubiquitous feature associated with cancer, including hepatocellular carcinoma (HCC). Analyses of 1,225 clinical HCC samples revealed that a large numbers of RNA binding proteins (RBPs) are dysregulated and that RBP dysregulation is associated with poor prognosis. We further identified that oncogenic activation of a top candidate RBP, negative elongation factor E (NELFE), via somatic copy-number alterations enhanced MYC signaling and promoted HCC progression. Interestingly, NELFE induces a unique tumor transcriptome by selectively regulating MYC-associated genes. Thus, our results revealed NELFE as an oncogenic protein that may contribute to transcriptome imbalance in HCC through the regulation of MYC signaling.

Latest Articles:

HDAC Inhibitors Finally Open Up: Chromatin Accessibility Signatures of CTCL

2017-07-10

[10.1016/j.ccell.2017.06.008]

Redefining Hormonal Therapy for Advanced Prostate Cancer: Results from the LATITUDE and CHAARTED Studies

2017-07-10

[10.1016/j.ccell.2017.06.007]

MUC-king with HIF May Rewire Pyrimidine Biosynthesis and Curb Gemcitabine Resistance in Pancreatic Cancer

2017-07-10

[10.1016/j.ccell.2017.06.006]

Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology

2017-07-10

[10.1016/j.ccell.2017.06.005]

MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer

2017-07-10

[10.1016/j.ccell.2017.06.004]

More Articles...